Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 2691014, 9 pages
https://doi.org/10.1155/2018/2691014
Research Article

Short-Term Treatment with Esmolol Reverses Left Ventricular Hypertrophy in Adult Spontaneously Hypertensive Rats via Inhibition of Akt/NF-κB and NFATc4

1Departamento de Anestesiología, Hospital General Universitario Gregorio Marañón, Doctor Esquero 46, 28007 Madrid, Spain
2Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
3Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
4Pfizer, CVMED, 610 Main Street, Cambridge, MA, USA
5Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

Correspondence should be addressed to Begoña Quintana-Villamandos; moc.liamg@itniuqogeb

Received 28 October 2017; Revised 24 December 2017; Accepted 3 January 2018; Published 18 February 2018

Academic Editor: François Roubille

Copyright © 2018 Begoña Quintana-Villamandos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Y. Lip, “Regression of left ventricular hypertrophy and improved prognosis: some hope now . . . or hype?” Circulation, vol. 104, pp. 1582–1584, 2001. View at Google Scholar
  2. S. M. Artham, C. J. Lavie, R. V. Milani, D. A. Patel, A. Verma, and H. O. Ventura, “Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression,” Progress in Cardiovascular Diseases, vol. 52, no. 2, pp. 153–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. H. Fagard, H. Celis, L. Thijs, and S. Wouters, “Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies,” Hypertension, vol. 54, no. 5, pp. 1084–1091, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Ferreira Filho, LC. Abreu, VE. Valenti et al., “Anti-hypertensive drugs have different effects on ventricular hypertrophy regression,” Clinics, vol. 65, pp. 723–728, 2010. View at Google Scholar
  5. B. Quintana-Villamandos, M. J. Delgado-Martos, J. J. Sanchez-Hernandez et al., “Early regression of left ventricular hypertrophy after treatment with esmolol in an experimental rat model of primary hypertension,” Hypertens Res, vol. 36, pp. 408–413, 2013. View at Google Scholar
  6. D. B. Wiest and J. S. Haney, “Clinical pharmacokinetics and therapeutic efficacy of esmolol,” Clinical Pharmacokinetics, vol. 51, no. 6, pp. 347–356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. K. Yu, G. Tait, K. Karkouti, D. Wijeysundera, S. McCluskey, and W. S. Beattie, “The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials,” Anesth Analg, vol. 112, pp. 267–281, 2011. View at Google Scholar
  8. K. P. Garnock-Jones, “Esmolol: A Review of its Use in the Short-Term Treatment of Tachyarrhythmias and the Short-Term Control of Tachycardia and Hypertension,” Drugs, vol. 72, no. 1, pp. 109–132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Bai and R. Hui, “Dimethylarginine dimethylaminohydrolase (DDAH)—a critical regulator of hypertensive left ventricular hypertrophy?” Medical Hypotheses, vol. 70, no. 5, pp. 962–966, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Quintana-Villamandos, A. Arnalich-Montiel, S. Arribas et al., “Early regression of coronary artery remodeling with esmolol and DDAH/ADMA pathway in hypertensive rats,” Hypertension Research, vol. 39, no. 10, pp. 692–700, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Quintana-Villamandos and E. Delgado-Baeza, “Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?” Medical Hypotheses, vol. 87, pp. 44–47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. C. M. Sag, C. X. C. Santos, and A. M. Shah, “Redox regulation of cardiac hypertrophy,” Journal of Molecular and Cellular Cardiology, vol. 73, pp. 103–111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. M. Shah and D. L. Mann, “In search of new therapeutic targets and strategies for heart failure: Recent advances in basic science,” The Lancet, vol. 378, no. 9792, pp. 704–712, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Heineke and J. D. Molkentin, “Regulation of cardiac hypertrophy by intracellular signalling pathways,” Nature Reviews Molecular Cell Biology, vol. 7, no. 8, pp. 589–600, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Simko and O. Pechanova, “Remodelling of the heart and vessels in experimental hypertension: advances in protection,” Journal of Hypertension, vol. 28, supplement 1, pp. S1–S6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. C. S. Mesquita, R. Oliveira, F. Bento, D. Geraldo, J. V. Rodrigues, and J. C. Marcos, “Simplified 2,4-dinitrophenylhydrazine spectrophotometric assay for quantification of carbonyls in oxidized proteins,” Analytical Biochemistry, vol. 458, pp. 69–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Condezo-Hoyos, M. Rubio, S. M. Arribas et al., “A plasma oxidative stress global index in early stages of chronic venous insufficiency,” Journal of Vascular Surgery, vol. 57, no. 1, pp. 205–213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Campos, R. Guzmán, E. López-Fernández, and Á. Casado, “Evaluation of the copper(II) reduction assay using bathocuproinedisulfonic acid disodium salt for the total antioxidant capacity assessment: the CUPRAC-BCS assay,” Analytical Biochemistry, vol. 392, no. 1, pp. 37–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. W. E. Stansfield, M. Ranek, A. Pendse et al., The Pathophysiology of Cardiac Hypertrophy and Heart Failure. Cellular and Molecular Pathobiology of Cardiovascular Disease, Chapter 4, Academic Press, San Diego, calif, USA, 2014.
  20. B. C. Bernardo, K. L. Weeks, L. Pretorius, and J. R. McMullen, “Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies,” Pharmacology & Therapeutics, vol. 128, no. 1, pp. 191–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. van Berlo, M. Maillet, and J. D. Molkentin, “Signaling effectors underlying pathologic growth and remodeling of the heart,” The Journal of Clinical Investigation, vol. 123, no. 1, pp. 37–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Li, J. Li, X. Cai et al., “Protein kinase D3 is a pivotal activator of pathological cardiac hypertrophy by selectively increasing the expression of hypertrophic transcription factors,” The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40782–40791, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Zangrillo, S. Turi, G. Crescenzi et al., “Esmolol Reduces Perioperative Ischemia in Cardiac Surgery: A Meta-analysis of Randomized Controlled Studies,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 23, no. 5, pp. 625–632, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Landoni, S. Turi, G. Biondi-Zoccai et al., “Esmolol Reduces Perioperative Ischemia in Noncardiac Surgery: A Meta-analysis of Randomized Controlled Studies,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 24, no. 2, pp. 219–229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Strulovici, R. A. Cerione, B. F. Kilpatrick, M. G. Caron, and R. J. Lefkowitz, “Direct demonstration of impaired functionality of a purified desensitized β-adrenergic receptor in a reconstituted system,” Science, vol. 225, no. 4664, pp. 837–840, 1984. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. MacDonnell, H. Kubo, D. L. Crabbe et al., “Improved myocardial β-adrenergic responsiveness and signaling with exercise training in hypertension,” Circulation, vol. 111, no. 25, pp. 3420–3428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Boknik, I. Heinroth-Hoffmann, U. Kirchhefer et al., “Enhanced protein phosphorylation in hypertensive hypertrophy,” Cardiovascular Research, vol. 51, pp. 717–728, 2001. View at Google Scholar
  28. D. Bai, L. Ueno, and P. K. Vogt, “Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt,” International Journal of Cancer, vol. 125, no. 12, pp. 2863–2870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Abeyrathna and Y. Su, “The critical role of Akt in cardiovascular function,” Vascular Pharmacology, vol. 74, pp. 38–48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. W.-W. Kuo, C.-Y. Chu, C.-H. Wu et al., “Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats,” Cell Biochemistry & Function, vol. 23, no. 5, pp. 325–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. W. B. Zhang, Q. J. Du, H. Li et al., “The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats,” Journal of Cellular & Molecular Medicine, vol. 16, no. 9, pp. 2227–2237, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. N. H. Purcell, G. Tang, C. Yu, F. Mercurio, J. A. DiDonato, and A. Lin, “Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 98, no. 12, pp. 6668–6673, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. O. N. Ozes, L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner, “NF-κB activation by tumour necrosis factor requires tie Akt serine-threonine kinase,” Nature, vol. 401, no. 6748, pp. 82–85, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Zelarayan, A. Renger, C. Noack et al., “NF-κB activation is required for adaptive cardiac hypertrophy,” Cardiovascular Research, vol. 84, no. 3, pp. 416–424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Liu, Y. Chen, M. Auger-Messier, and J. D. Molkentin, “Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling,” Circulation Research, vol. 110, no. 8, pp. 1077–1086, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Zou, X. Gan, H. Zhou et al., “Alpha-lipoic acid attenuates cardiac hypertrophy via inhibition of C/EBPβ activation,” Molecular and Cellular Endocrinology, vol. 399, pp. 321–329, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Arnalich-Montiel, M. C. Gonzalez, E. Delgado-Baeza et al., “Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity,” BioMed Research International, vol. 2014, Article ID 531087, 9 pages, 2014. View at Publisher · View at Google Scholar
  38. A. S. Veskoukis, M. G. Nikolaidis, A. Kyparos, and D. Kouretas, “Blood reflects tissue oxidative stress depending on biomarker and tissue studied,” Free Radical Biology & Medicine, vol. 47, no. 10, pp. 1371–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Zhang, A. Perino, A. Ghigo, E. Hirsch, and A. M. Shah, “NADPH oxidases in heart failure: poachers or gamekeepers?” Antioxidants & Redox Signaling, vol. 18, no. 9, pp. 1024–1041, 2013. View at Publisher · View at Google Scholar · View at Scopus